Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting
Organon announced that a new pooled analysis of Phase 3 data for VTAMA cream will be presented at the 2026 Society for Pediatric Dermatology Annual Meeting. The analysis evaluates the efficacy and safety of VTAMA across pediatric and adult age groups using data from the pivotal ADORING 1 and ADORING 2 trials for moderate to severe atopic dermatitis.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.